Objective The trial was designed to evaluate the safety and performance of the ev3 Protégé TM stent in the treatment of de novo or re-stenotic common and/or internal carotid artery stenoses with adjunctive u...Objective The trial was designed to evaluate the safety and performance of the ev3 Protégé TM stent in the treatment of de novo or re-stenotic common and/or internal carotid artery stenoses with adjunctive use of a CE-marked filter embolic protection device.Methods This study was a prospective multi-center, single-arm trial. Between June and October 2003, 77 patients were enrolled in 8 investigational centers throughout Europe. The primary endpoint was the incidence of Major Neurological Events (MANE) through one month. Other endpoints were the ability to properly place the stent, and primary patency and MANE after six months. Eligible for the study were patients with a de novo or restenotic target lesion located in the common and/or internal carotid artery (>70% stenosis for asymptomatic and >50% stenosis for symptomatic patients). The ev3 Spider (Embolic Protection Filter was used in 75 of 77 cases. Results In 76 out of the 77 patients (99%), the stent could be successfully implanted with a residual stenosis ≤30% as criterion. Of the 74 patients that had a carotid ultrasound at one month follow-up, none had a re-stenosis of the target lesion. There were three MANEs during or immediately after the procedure (3.9%), two were major and one was a minor stroke. There were eight severe complications (9.1%); six of these happened during or immediately after the procedure and were related to the procedure, none was related to the device. They are resolved without sequelae. No deaths have occurred.Conclusions The Protégé stent is safe and performs well in the treatment of carotid artery stenosis. The technical success rate for placement of the Protégé stent as assessed by the residual stenosis post implant was very high and all stents were successfully deployed. The incidence of MANE was comparable with that in other recent carotid stent studies and still lower than standard CEA.展开更多
混洗差分隐私(SDP)模型能兼顾用户端的隐私保护程度和服务器端发布结果的可用性,更适用于隐私保护的大数据收集和统计发布场景。针对目前SDP频率估计方法的洗牌效率较低和混洗过程安全性不足等问题,进行以下工作:首先,设计基于优化椭圆...混洗差分隐私(SDP)模型能兼顾用户端的隐私保护程度和服务器端发布结果的可用性,更适用于隐私保护的大数据收集和统计发布场景。针对目前SDP频率估计方法的洗牌效率较低和混洗过程安全性不足等问题,进行以下工作:首先,设计基于优化椭圆曲线的混洗差分隐私盲签名算法(SDPBSA),以实现对篡改或伪造信息的鉴别,提高混洗过程的安全性;其次,提出矩阵列重排转置(MCRT)洗牌方法,以利用随机的矩阵列重排和矩阵转置操作实现数据混洗,提高混洗过程的效率;最后,结合上述方法构建完整的SDP频率估计隐私保护框架——SM-SDP(SDP based on blind Signature and Matrix column rearrangement transposition),并通过理论分析讨论它的隐私性和误差级别。在Normal、Zipf和IPUMS(Integrated Public Use Microdata Series)等数据集上的实验结果表明,相较于Fisher-Yates、ORShuffle(Oblivious Recursive Shuffling)和MRS(Message Random Shuffling)等洗牌方法,MCRT洗牌方法的洗牌效率提升了1~2个数量级;相较于mixDUMP、PSDP(Personalized Differential Privacy in Shuffle model)和HP-SDP(Histogram Publication with SDP)等频率估计方法,SM-SDP框架在不同比例恶意数据存在时的均方误差(MSE)降低了2~11个数量级。展开更多
文摘Objective The trial was designed to evaluate the safety and performance of the ev3 Protégé TM stent in the treatment of de novo or re-stenotic common and/or internal carotid artery stenoses with adjunctive use of a CE-marked filter embolic protection device.Methods This study was a prospective multi-center, single-arm trial. Between June and October 2003, 77 patients were enrolled in 8 investigational centers throughout Europe. The primary endpoint was the incidence of Major Neurological Events (MANE) through one month. Other endpoints were the ability to properly place the stent, and primary patency and MANE after six months. Eligible for the study were patients with a de novo or restenotic target lesion located in the common and/or internal carotid artery (>70% stenosis for asymptomatic and >50% stenosis for symptomatic patients). The ev3 Spider (Embolic Protection Filter was used in 75 of 77 cases. Results In 76 out of the 77 patients (99%), the stent could be successfully implanted with a residual stenosis ≤30% as criterion. Of the 74 patients that had a carotid ultrasound at one month follow-up, none had a re-stenosis of the target lesion. There were three MANEs during or immediately after the procedure (3.9%), two were major and one was a minor stroke. There were eight severe complications (9.1%); six of these happened during or immediately after the procedure and were related to the procedure, none was related to the device. They are resolved without sequelae. No deaths have occurred.Conclusions The Protégé stent is safe and performs well in the treatment of carotid artery stenosis. The technical success rate for placement of the Protégé stent as assessed by the residual stenosis post implant was very high and all stents were successfully deployed. The incidence of MANE was comparable with that in other recent carotid stent studies and still lower than standard CEA.
基金国家自然科学基金(62272077,72301050)重庆市教委科技重大项目(KJZD-M202400604)资助+1 种基金the Natural ScienceFoundation of Chongqing,China(No.cstc2021jcyj msxmX0557)the MOE Layout Foundation of Humanities and Social Sciences,China(No.20YJAZH102).
文摘在对享受基于位置服务(LBS)用户进行位置隐私保护时,传统k-匿名技术在执行匿名操作时没有全面考虑时间开销和位置背景信息。针对上述问题,提出了一种基于Alt-Geohash编码的k-匿名位置隐私保护方案(k-anonymous location privacy protection scheme based on Alt-Geohash coding,KLPPS-AGC)。首先,通过位置泛化和Alt-Geohash编码技术实现对历史数据的快速检索;其次,根据历史查询概率筛选出能与用户构建高位置熵的位置;再次,利用海伦公式改善匿名集的位置分散度;最后,构建安全匿名集实现对用户的位置隐私保护。实验证明,该方案拥有较低的时间开销和较高的隐私性。
文摘混洗差分隐私(SDP)模型能兼顾用户端的隐私保护程度和服务器端发布结果的可用性,更适用于隐私保护的大数据收集和统计发布场景。针对目前SDP频率估计方法的洗牌效率较低和混洗过程安全性不足等问题,进行以下工作:首先,设计基于优化椭圆曲线的混洗差分隐私盲签名算法(SDPBSA),以实现对篡改或伪造信息的鉴别,提高混洗过程的安全性;其次,提出矩阵列重排转置(MCRT)洗牌方法,以利用随机的矩阵列重排和矩阵转置操作实现数据混洗,提高混洗过程的效率;最后,结合上述方法构建完整的SDP频率估计隐私保护框架——SM-SDP(SDP based on blind Signature and Matrix column rearrangement transposition),并通过理论分析讨论它的隐私性和误差级别。在Normal、Zipf和IPUMS(Integrated Public Use Microdata Series)等数据集上的实验结果表明,相较于Fisher-Yates、ORShuffle(Oblivious Recursive Shuffling)和MRS(Message Random Shuffling)等洗牌方法,MCRT洗牌方法的洗牌效率提升了1~2个数量级;相较于mixDUMP、PSDP(Personalized Differential Privacy in Shuffle model)和HP-SDP(Histogram Publication with SDP)等频率估计方法,SM-SDP框架在不同比例恶意数据存在时的均方误差(MSE)降低了2~11个数量级。
